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Abstract
The synthesis of antimicrobial thymol/carvacrol-loaded polythioether nanoparticles (NPs) via a
one-pot, solvent-free miniemulsion thiol-ene photopolymerization process is reported. The active
antimicrobial agents, thymol and carvacrol, are employed as “solvents” for the thiol-ene monomer
phase in the miniemulsion to enable facile high capacity loading (≈50% w/w), excellent
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encapsulation efficiencies (>95%), and elimination of all postpolymerization purification
processes. The NPs serve as high capacity reservoirs for slow-release and delivery of thymol/
carvacrol-combination payloads that exhibit inhibitory and bactericidal activity (>99.9% kill
efficiency at 24 h) against gram-positive and gram-negative bacteria, including both saprophytic
(Bacillus subtilis ATCC 6633 and Escherichia coli ATCC 25922) and pathogenic species (E. coli
ATCC 43895, Staphylococcus aureus RN6390, and Burkholderia cenocepacia K56-2). This report
is among the first to demonstrate antimicrobial efficacy of essential oil-loaded nanoparticles
against B. cenocepacia – an innately resistant opportunistic pathogen commonly associated with
debilitating respiratory infections in cystic fibrosis. Although a model platform, these results point
to promising pathways to particle-based delivery of plant-derived extracts for a range of
antimicrobial applications, including active packaging materials, topical antiseptics, and innovative
therapeutics.

Author Manuscript

1. Introduction
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Microbial threats, particularly multidrug-resistant (MDR) bacterial strains and other
emerging pathogens, are greatly impacting public health, burdening healthcare systems, and
have potential to disrupt socioeconomic infrastructures in both developing and industrialized
nations. In the United States alone, the Center for Disease Control estimates at least two
million illnesses and 23 000 deaths are attributed to multidrug-resistant bacterial infections
each year. Annually, these cases account for ≈$20 billion in excess health care costs and up
to $35 billion in lost productivity due to sick leave and hospitalizations.[1] While
Staphylococcus aureus and Pseudomonas aeruginosa tend to dominate the MDR discussion,
other microorganisms, such as Burkholderia cepacia complex (Bcc), have emerged as
opportunistic pathogens with significant clinical importance in persons with cystic fibrosis
(CF).[2] Pulmonary colonization with Burkholderia cenocepacia, the most common isolate
of the 18 member Bcc, results in severe respiratory infections in persons with CF and is
associated with high morbidity and mortality rates.[3] Effective treatments for B.
cenocepacia infections are rare, as these bacteria exhibit high intrinsic resistance to most
antibiotics.[4] In general, the MDR microbial threat extends far beyond the effect on humans,
and additionally impacts animal agriculture and veterinary medicine. The continuous
emergence of MDR pathogens and scarcity of new antimicrobial drug scaffolds in the
pharmaceutical discovery pipeline have led to growing interest in natural, plant-derived
extracts as alternatives to synthetic antibiotics.[5] In this direction, essential oils (EOs) –
typically complex extracts from aromatic plants comprising mixtures of aldehydes, terpenes,
and phenols – are well known to exhibit broad spectrum biological and antimicrobial
activity.[6,7] With many EOs identified as “Generally Regarded as Safe,” these extracts have
been actively explored and continue to garner interest as food preservatives and packaging
constituents,[8,9] textile fragrances,[10] pesticides,[11] and other antimicrobial therapeutic
applications.[12–14]
Monoterpene phenol isomers, carvacrol and thymol, are major constituents of EOs extracted
from oregano, thyme, and other plants belonging to the Lamiaceae family. These isomers
show antiviral, antifungal, and broad spectrum antibacterial properties against both gramnegative and gram-positive bacteria, including MDR and biofilm forming
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microorganisms.[15,16] In one promising example, EO extracts containing carvacrol and
thymol as primary constituents were shown to inhibit the growth of several environmental
and clinical bacterial strains belonging to the B. cepacia complex.[17] The broad spectrum of
activity of these isomers has been attributed to multiple modes of toxicity; however, the
primary site of toxicity is the cell membrane.[16] In general, these hydrophobic isomers act
by partitioning into the cytoplasmic membrane leading to increased permeability, depletion
of proton gradients, and subsequent disruption of adenosine triphosphate (ATP) synthesis.
The collapse of the proton motive force and depletion of the ATP pool eventually lead to cell
death.

Author Manuscript
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A major challenge for the practical application of carvacrol and thymol as antimicrobial
agents stems from the hydrophobicity (poor water solubility), volatility, and instability of
these EO constituents. Poor water solubility, in particular, limits the bioavailability of these
compounds and significantly lowers their biological and antimicrobial activity, whereas
volatility is problematic for achieving sustained release and controlled delivery. To address
these challenges, a variety of approaches have been reported to encapsulate hydrophobic EO
constituents as colloidal systems, including oil-in-water emulsions, microemulsions, and
nanoemulsions; molecular inclusion complexes; lipid-based carriers (e.g., liposomes and
solid lipid nanocapsules);[18] and polymer-based carriers (e.g., films, micro/nanocapsules,
and nanoparticles).[5,19,20] Polymer nanoparticles (PNPs) are advantageous in that they offer
a highly flexible delivery platform for antimicrobial applications, where nanoparticle
properties (e.g., morphology, bulk/surface composition, and size) are readily tunable using a
variety of synthetic approaches.[21–24] In turn, these tunable PNP properties dictate
important features such as particle stability, surface interactions, and EO loading and release
kinetics. In this direction, researchers have successfully incorporated carvacrol, thymol, and
other phenolic EO constituents into various PNP matrices (chitosan,[25] poly(lactide-coglycolide),[26,27] methylcellulose,[28] and zein[29]) via emulsification-evaporation,[26,27]
emulsification-solvent exchange,[28] and nanoprecipitation[29] methods. While these
examples demonstrate facile fabrication, encapsulation, and exhibit antimicrobial activity,
many suffer several deficiencies such as low EO loading (i.e., 3% w/w carvacrol in chitosan
matrix), poor EO encapsulation efficiencies (e.g., 14%–31% carvacrol-in-water emulsion
and ionic gelation of chitosan),[30] use of organic solvents during encapsulation (acetone,
ethanol, dichloromethane),[26,29] and burst release profiles of EO.[26,27]

Author Manuscript

Miniemulsion polymerization is ideally suited for encapsulation of hydrophobic payloads
(e.g., lipophilic drugs, pigments, fragrances, inorganic nanomaterials, and polymers) with
high loading and encapsulation efficiencies,[31–33] but has received little attention for
sequestration and delivery of essential oils – particularly toward antimicrobial applications.
Miniemulsion polymerizations are described as aqueous dispersions of small, narrowly
distributed monomer droplets stabilized against Ostwald ripening and collisional degradation
by addition of an appropriate surfactant and costabilizer. Monomer droplets ranging in size
from 50–500 nm are attained via high shear mixing – typically either high-pressure
homogenization or ultrasonic processing – and subsequently serve as discrete nanoreactors
for the formation of polymer nanoparticles upon polymerization. Since mass transport
between monomer droplets is suppressed, encapsulation of hydrophobic materials requires a
straightforward addition of the desired material to the organic phase prior to shear mixing.
Adv Healthc Mater. Author manuscript; available in PMC 2017 June 17.
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Thus, encapsulation of materials miscible with the monomer phase provides polymer
nanoparticles with the payload dispersed throughout the polymer matrix (whereas
immiscible materials provide a route to nanocapsules).[33] Recently, we and others have
reported thiol-ene[34–37] and thiol-alkyne[38,39] polymerization in miniemulsion as a facile
platform for the synthesis of crosslinked polythioether nanoparticles with tunable particle
sizes, tailorable network properties, and clickable surface functionality. More importantly,
we demonstrated the ability to encapsulate hydrophobic inorganic nanoparticles within the
polythioether matrix with high efficiency without sacrificing the rapid polymerization
kinetics and high conversions provided by the thiol-mediated photopolymerization process.
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Herein, we report a facile, one-pot approach to encapsulate monoterpene phenols (carvacrol/
thymol) within polythioether nanoparticles as a model, sustained-release antimicrobial
platform. We employ thiol-ene photopolymerization in miniemulsion for rapid nanoparticle
synthesis, where carvacrol and thymol serve as miscible compatibilizers in the monomer
phase enabling solvent-free encapsulation with high loading capacities (33%–66% w/w, EO
relative to the NP) and excellent encapsulation efficiencies (>95%). The absence of solvent
and use of a polymerizable surfactant eliminate the need for any postpolymerization
purification steps. Release studies reveal the polythioether nanoparticles function as
sustained-release reservoirs for carvacrol/thymol – discharging less than 4% of the payload
over 24 h. The thymol/carvacrol-loaded (TCNPs) nanoparticles show effective antimicrobial
activity (>99.9% kill efficiency at 24 h) against gram-positive (Bacillus subtilis and
Staphylococcus aureus) and gram-negative (Escherichia coli and Burkholderia cenocepacia)
bacteria. Considering the innate resistance of the bacterial strain, the high efficacy of TCNPs
against Burkholderia cenocepacia is particularly significant, and to our knowledge,
represents the first demonstration of antibacterial efficacy against B. cenocepacia using
thymol/carvacrol-loaded polymer nanoparticles.

2. Results and Discussion
2.1. Synthesis and Characterization of Essential Oil Encapsulated Nanoparticles

Author Manuscript

Polythioether NPs loaded with various ratios of carvacrol/thymol were synthesized via thiolene photopolymerization in miniemulsion according to Figure 1a. NPs were prepared by
dispersing the organic phase, comprising diallyl phthalate (DAP), glycol di(3mercaptopropionate) (GDMP), pentaerythritol tetra(3-mercaptopropionate) (PETMP), and
carvacrol/thymol into deionized water containing surfactant via probe ultrasonication for 25
min (Figure 1b). The full details for the miniemulsion formulation are given in Table S1
(Supporting Information). The monomer droplets were then photopolymerized by exposure
to UV light (λmax 365 nm). Control NPs (without carvacrol/thymol) were similarly prepared
using butyl acetate as a diluent for the organic phase. After ultrasonication and
photopolymerization, aliquots were removed and analyzed via proton nuclear magnetic
resonance spectroscopy (1H NMR) (Figure S1, Supporting Information) in D2O. The
disappearance of the peaks attributed to the thiol (–CH2CH2–SH, 2.62–2.83 ppm) and
alkene (5.07–5.45, 5.87–6.10 ppm) from the monomers, and broadening of other peaks
indicated the thiol-ene photopolymerization proceeded to high conversion. Additionally,
Raman spectroscopy of freshly emulsified nanoparticles prior to and after UV
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polymerization showed the disappearance of SH (2580 cm−1) and alkene stretches (1640–
1680 cm−1) (Figure S2, Supporting Information). The ability to achieve high thiol-ene
monomer conversion in the presence of phenolic functional groups is in good agreement
with our previous work.[38,40,41] At near quantitative conversions, crosslink density (0.168 ×
10−3 mol cm−3) of the polythioether NPs was estimated from the rubbery plateau storage
modulus (1.25 MPa, Tg −12.1 °C, Figure S3, Supporting Information) of the base thiol-ene
resin (i.e., GDMP+PETMP+diallyl phthalate prepared at identical stoichiometric ratios used
in the miniemulsions) at Tg + 40 °C according to the theory of rubber elasticity.[42] To
eliminate surfactant leaching, Hitenol BC-20 was employed as a polymerizable surfactant to
covalently incorporate the surfactant into the thiol-ene network (discussed further in the
antimicrobial section). A series of exploratory NP syntheses were conducted, in which the
concentration of Hitenol BC-20 (Figure S4a, Supporting Information) and organic weight
fraction (Figure S4b, Supporting Information) were independently varied, to identify
conditions to provide acceptable NP size and size distributions. A 4.5 wt% organic phase
and 70 × 10−3 M Hitenol BC-20 were identified as optimum parameters; these conditions
provided pure carvacrol-loaded NPs (CNPs), thymol/carvacrol-loaded NPs (TCNPs), and
control NPs with mean particle sizes of 148 ± 24 (PDI: 0.560), 147 ± 19 (PDI: 0.387), and
183 ± 19 nm (PDI: 0.473), respectively, as determined by dynamic light scattering (DLS).
We note that the reported std. dev. values represent the deviation in the average particle size
obtained from a minimum of three separate syntheses. A representative transmission
electron microscopy (TEM) image for TCNPs loaded with a 0.75:1 T:C ratio (Figure 1c)
showed spherical particles with sizes in good agreement with DLS analysis. TEM for the
control NPs and CNPs are shown in Figure S5a,b, respectively. The salient feature of this
synthetic approach is that the carvacrol/thymol constituents serve as the “solvent” for the
organic phase in the miniemulsion process. This route enabled a high loading capacity of
thymol/carvacrol within the NPs (between 33% and 66% w/w, EO/NP) with high
encapsulation efficiencies (>95% by GC-MS), eliminated the need for an organic solvent
during NP synthesis, and provided a one-pot approach to EO encapsulation without any
postpolymerization purification processes (e.g., no freeze drying, evaporation, and extraction
processes were required). Thus, the NP dispersions obtained from the previously described
synthetic approach were used directly for the antimicrobial studies detailed below.
2.2. Loading and Release of Thymol and Carvacrol

Author Manuscript

Next, we investigated the kinetics of carvacrol and carvacrol/thymol mixtures released from
polythioether NPs into water. The amount of essential oil released was quantified by
measuring the concentration of carvacrol/thymol available in water via GC-MS at 0, 4, 8,
and 12 h. Figure 2a shows the release data for CNPs (synthesized at 33% w/w C/NP) and
TCNPs (synthesized with 47% w/w TC/NP, 0.75:1 T:C). The EOload data points represent the
total amount of carvacrol (16 ± 0.7 mg mL−1) and thymol/carvacrol (25 ± 5 mg mL−1)
loaded into the NPs during miniemulsion photopolymerization, and are in good agreement
with initial formulations for each type of NP. The ratio of the time 0 and EOload
concentrations represents the encapsulation efficiency for the miniemulsion process, i.e.,
≈96.9% for TCNPs and 96.8% for CNPs. Thus, the concentration of EO within the
nanoparticles is up to 20 times higher than the reported solubility limits for thymol (0.85 mg
mL−1) and carvacrol (1.25 mg mL−1) at 20 °C.[43] As shown in Figure 2a, the concentration
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of EO released from the NPs in water was relatively constant over 24 h, where TCNPs and
CNPs reached plateau concentrations between 0.7–0.9 mg mL−1 and 0.5–0.6 mg mL−1,
respectively. These concentrations correspond to less than 4% release of the total EO
payload over 24 h, (Figure 2b) and approach the solubility limit of thymol and carvacrol in
water at 20 °C. These results suggest that the polythioether nanoparticles effectively serve as
a reservoir for the hydrophobic carvacrol and thymol compounds. This “reservoir effect”
enables extended delivery of EO constituents into the bulk aqueous phase, where the
solubility limit of the relatively insoluble compounds ultimately dictates the aqueous-phase
equilibrium concentration.
2.3. Antimicrobial Properties
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Antimicrobial activity of the EO-containing NPs was evaluated against a panel of grampositive and gram-negative bacteria that included both saprophytic (B. subtilis ATCC 6633
and E. coli ATCC 25922) and pathogenic species (E. coli ATCC 43895 [serotype O157:H7],
S. aureus RN6390, and B. cenocepacia K56-2). Our preliminary experiments revealed that
control NPs prepared using either sodium dodecyl sulfate or cetyltrimethylammonium
bromide as surfactant exhibited antimicrobial activity, presumably due to surfactant
leaching. Thus, we chose Hitenol BC-20 – a commercially available polymerizable
surfactant – for further experiments, as it exhibited no measurable antimicrobial activity in
zone of inhibition (ZOI) experiments at the concentration used in NP synthesis (70 × 10−3 M
Figure 3a; 140 × 10−3 M Figure S6, Supporting Information). More importantly, control NPs
prepared with Hitenol BC-20 showed no measureable ZOI against all five bacteria (Figure
3b). Initially, we evaluated the antimicrobial activity of NPs containing pure carvacrol (33%
w/w, carvacrol relative to NP) and various ratios of thymol:carvacrol (Treatment I – 66%
w/w, 3:1 T:C; Treatment II – 55% w/w, 1.5:1 T:C; and Treatment III – 47% w/w, 0.75:1)
against E. coli ATCC 25922, S. aureus RN6390, and B. subtilis ATCC 6633 (Figure S7,
Supporting Information). Since thymol is a solid at room temperature (mp 49–51 °C),
thymol-loaded NPs were difficult to synthesize using a solvent-free approach and were not
actively pursued in this work. Previous reports have shown that combinations of thymol and
carvacrol exhibit higher antimicrobial activity than each individual constituent,[16] thus,
carvacrol-loaded NPs were evaluated via ZOI only as a comparison to NPs loaded with
combinations of thymol/carvacrol. Interestingly, all treatments with NPs containing thymol/
carvacrol showed similar zones of inhibition (Figure S7, Supporting Information), thus
treatment III, with the lowest overall thymol/carvacrol loading, was chosen for the
experiments discussed hereafter. From this point forward, the acronym TCNP will refer to
nanoparticles loaded with 47% w/w, 0.75:1 T:C (treatment III). Figure 3c,d shows the results
of well diffusion assays for CNPs and TCNPs against the full panel of bacteria. As shown in
Figure 3c, CNPs exhibited moderate activity against all bacteria (ZOI 1–2 mm). As expected,
TCNPs were consistently more effective than CNPs, as indicated by the larger ZOIs shown in
Figure 3d. TCNPs inhibited the growth of all five bacteria, including S. aureus (2 mm ZOI)
and B. cenocepacia (3 mm ZOI) that are known to exhibit high intrinsic resistance to
conventional antibiotics. Bacillus subtilis (6 mm ZOI) was the most susceptible species to
the TCNP treatment.
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The antimicrobial activity of TCNPs was further evaluated via determination of the minimum
inhibitory concentration (MIC). The MIC is defined as the lowest concentration of an
antimicrobial agent that inhibits the growth of a microorganism following an overnight
incubation period. We adopted a modified broth microdilution method to determine MICs
for NP-loaded thymol/carvacrol.[44] We also spot-plated bacteria that were incubated with
NPs to check for possible bacteriostatic effects. While MIC assays are reputable for
accuracy and standardized comparison across numerous antibiotics, the conventional MIC
output presents a challenge for hydrophobic antibiotics encapsulated in polymer
nanoparticles – and is particularly problematic for NP delivery systems that function via the
“reservoir effect.” As a result of the “reservoir effect,” the concentration loaded in the
nanoparticle may be orders of magnitude greater than the concentration delivered to the
bacteria during the time frame of the MIC assay. For example, the loaded concentration of
thymol/carvacrol in TCNPs was determined to be 25 000 μg mL−1 by GC-MS. These thymol/
carvacrol loading levels are up to 100-fold higher than reported MIC values for E. coli
ATCC 25922 (MICcarvacrol: 225 μg mL−1, MICthymol: 225 μg mL−1) and S. aureus
(MICcarvacrol: 450 μg mL−1, MICthymol: 225 μg mL−1);[45] however, our release studies show
that carvacrol and thymol are delivered to the bulk aqueous phase at a relatively constant
concentration of 500–900 μg mL−1 over 24 h. Following the precedent of Langer and coworkers,[46] who previously noted the difficulty in defining the MIC for antibiotic-loaded
nanoparticles, we report concentrations as the total EO concentration within the NP at the
beginning of the treatment to identify the MIC. While the loaded concentrations grossly
overestimate the MIC value relative to a conventional definition, we reasoned this route of
reporting was the most useful and conservative measure of NP-loaded antimicrobial efficacy.
Additionally, we calculated the nanoparticle number density (number of particles per mL) to
estimate the number of NPs delivered in each experiment as an alternate MIC output value,
with the caveat that the number density is based on the average particle diameter of a
polydisperse nanoparticle population. Nonetheless, number density MIC provides a point of
comparison among the various bacteria investigated in this paper. Figure 4 shows the results
from the viability assays used to determine the MICs for TCNPs. In general, the growth of all
five bacteria included in this study was completely inhibited upon exposure to TCNPs loaded
at 25 000 μg mL−1 (1010 nanoparticles) in a 50 μL broth volume, which translated to ≈105
NPs per bacterial cell. B. subtilis was the most susceptible species, and was completely
inhibited at TCNPs loaded at 2 500 μg mL−1 (109 nanoparticles, ≈104 NPs per cell). The
MIC values are in good agreement with the previously described results of agar well
diffusion tests.
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We also investigated the kill kinetics for the panel of bacteria incubated with TCNPs using
live/dead and terminal dilution assays. Initially, the kill kinetics of TCNPs against B. subtilis
ATCC 6633 and E. coli ATCC 25922 were probed using a live/dead cell viability assay,
which stains “dead” bacteria red upon cell membrane damage and uptake of propidium
iodide. As shown in Figure 5a,b a large number of viable bacterial cells (stained green) were
observed for the B. subtilis and E. coli control samples, respectively. Incubation of TCNPs
with B. subtilis for 15 min yielded an apparent 50:50 live/dead ratio, whereas 30 min
resulted in mostly dead bacteria (Figure 5a). For E. coli ATCC 25922, the 50:50 live/dead
ratio was observed after two hours of incubation with TCNPs, and most bacteria stained dead
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after 8 h of incubation (Figure 5b). To quantify the kill kinetics for all five bacteria, we used
a terminal dilution assay. Figure 6a shows the log reduction in the bacteria count as a
function of incubation time with ≈1011 TCNPs. The log CFU reductions at 48 h are reported
as % kill values in Figure 6b. In agreement with our previous ZOI data, B. subtilis ATCC
6633 showed the highest susceptibility to the TCNP treatment with 4.3 and 7.1 log
reductions observed at 12 and 24 h, respectively. The log reductions for E. coli O157:H7
(ATCC 43895) were 3.5 at 12 h and 7 at 24 h — results that translate into a kill efficacy of
>99.99%. The viability of E. coli ATCC 25922 declined at a slower rate than E. coli
O157:H7, however, the 48 h exposure to TCNPs ultimately killed >99.99% of the bacteria.
Incubation of TCNPs with B. cenocepacia K56-2 produced 3.9 and 6.2 log reductions at 12
and 24 h, respectively. The kill kinetics and high susceptibility (over 99.99% efficacy at 24
h) of B. cenocepacia to the TCNPs is of particular interest, as these bacteria have very high
innate resistance to a wide range of antibiotics and biocides.[47] With a 3.6 log reduction, S.
aureus RN6390 was the only species that maintained viability after 24 h incubation with
TCNPs. However, a 6.3 log reduction, or >99.99 % kill efficacy for S. aureus was ultimately
attained at 48 h.

Author Manuscript

Finally, insight into the antimicrobial mechanism was investigated by visualizing the
microbial structure of B. subtilis ATCC 6633 and E. coli ATCC 25922 before and after
prolonged contact with TCNPs using electron microscopy. Prior to exposure to TCNPs, TEM
of both microbes showed intact cell structure (Figure 7, control). After exposure with TCNPs,
distinct indication of damage to the cell envelope (diffuse membrane, cellular debris) and
loss of flagella were visible in both E. coli ATCC 25922 (Figure 7a) and B. subtilis ATCC
6633 (Figure 7b). Additionally, the scanning electron microscopy (SEM) image of B.
subtilis after 24 h exposure to inhibitory concentrations of TCNPs showed bacteria with
crumpled cell envelopes and pore-like lesions, which is consistent with the collapse of the
cell structure (Figure 7c). These results are consistent with previously reported postulates
that identify the cell membrane as the primary site of toxicity for carvacrol/thymol.[16]

3. Conclusion
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We have reported a one-pot, solvent-free miniemulsion photopolymerization process for the
synthesis of thymol/carvacrol-loaded polythioether nanoparticles. Using the thymol/
carvacrol payload directly as a diluent for the monomer phase in the presence of a
polymerizable surfactant provided the active NPs without any postsynthetic purification. The
NPs serve as high capacity reservoirs for slow-release and delivery of thymol/carvacrolcombination payloads that exhibit inhibitory and bactericidal activity (>99.9% kill efficiency
at 24 h) against gram-positive (Bacillus subtilis and Staphylococcus aureus) and gramnegative (Escherichia coli and Burkholderia cenocepacia) bacteria. The simplicity,
modularity, and efficacy of the essential oil encapsulation platform may combat bacteria
with intrinsic resistance to conventional antibiotics, and is potentially adaptable for delivery
of EOs as active packaging materials and topical antiseptics. The antimicrobial activity of
TCNPs against inherently resistant Burkholderia cenocepacia may provide a route to
innovative pulmonary therapeutics by appropriately engineering the nanoparticle properties;
investigations of thymol/carvacrol-loaded NPs against B. cepacia complex biofilms — a
challenging form of the bacteria commonly associated with cystic fibrosis — are currently
Adv Healthc Mater. Author manuscript; available in PMC 2017 June 17.
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underway. In this direction, we are particularly interested to exploit the simple synthetic
modularity of this process for the design of EO-loaded biodegradable nanoparticles with
specific surface chemistries to serve as multimode (e.g., contact biocidal, targeted NPbacteria interactions) antimicrobial platforms.

4. Experimental Section
Materials

Author Manuscript

GDMP and PETMP were provided by Bruno Bock. Hexadecane, ethyl acetate, sodium
chloride, and thymol were obtained from Fisher Scientific. DAP, 4-p-methoxy phenol
(MEHQ), and butyl acetate were acquired from Sigma-Aldrich. Other reagents were
purchased from the following vendors: 1-hydroxycyclohexyl phenyl ketone (Irgacure 184)
from CIBA; Hitenol BC-20 from Montello, Inc.; carvacrol from TCI America. Difco Agar,
Mueller Hinton II agar (MHA), Mueller Hinton II broth (MHB), and Bacto Tryptone were
from Becton, Dickinson and Company. All the materials were obtained at the highest purity
available and used without further purification unless otherwise specified.
Characterization Methods
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The size and distribution of the NPs were measured by DLS using a Microtrac Nanotrac
Ultra NPA150 particle analyzer. Particle size and distribution were obtained using the
Microtrac Flex software (v.10.6.1), which employs non-negatively constrained least-squares
and cumulants analysis to obtain the intensity-weighted “z-average” mean particle size as
the first cumulant, and the polydispersity index from the second cumulant.[48] Transmission
electron micrographs were taken with a Zeiss 900 electron microscope operating at 50 kV
and outfitted with a Model 785 Erlangshen ES1000 WCCD camera (Gatan). Samples were
applied to 200 mesh copper grids (3.05 mm, 200 lines per inch square mesh, Electron
Microscopy Sciences) coated with Formvar (5% polyvinyl formal resin). Proton (1H) NMR
was recorded on a Bruker Acend 600 MHz spectrometer at 30 °C in D2O, using 128 scans
and a 4.27 s relaxation delay. Optical density (OD) and fluorescence readings were
performed in a BioTek Synergy 2 programmable microplate reader. Confocal images were
taken using a Zeiss LSM 510 confocal laser scanning microscope. High-resolution field
emission SEM (FE-SEM) was performed with a Zeiss SIGMA variable pressure field
emission scanning electron Microscope operating at 10 kV in high vacuum mode. Samples
were sputter coated with silver at instrument-reported thickness of 5 nm with a Quorum
Emitech K550X sputter coater. Raman spectra were acquired using a high-performance
portable Raman spectrometer (i-Raman Plus, B&W Tek Inc., Delaware, USA). The samples
were analyzed at 100 mW, with a 785 nm diode laser and 150 s accumulation time.
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General Nanoparticle Sample Preparation
Each nanoparticle synthesis was prepared in a 20 mL scintillation vial with a total volume of
10 mL. The organic stock solutions shown in Table S1 (Supporting Information) were added
into a vial containing a stock solution of Hitenol BC 20 and deionized water. As we
previously reported, MEHQ serves as a radical inhibitor to suppress thermal polymerization
during ultrasonication.[34] The samples were placed into an ice bath and sonicated using a
Qsonica Q700 probe ultrasonicator at 25% amplitude for 25 min. The resultant
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miniemulsions were cured for 15 min at an intensity of 185 mW cm−2 using an OmniCure
S1000 UV light source with a 100 W mercury lamp (λmax = 365 nm, 320–500 nm filter).
All samples were made in triplicate to ensure data reproducibility.
Preparation of Essential Oil Encapsulated Nanoparticles
Carvacrol encapsulated nanoparticles were prepared by replacing butyl acetate with 33%
w/w carvacrol as the solvent. For nanoparticles containing a combination of thymol and
carvacrol, 20% w/w thymol was added along with 27% w/w carvacrol. The total organic
fraction evaluated was 4.5% w/w for all samples.
Determination of nanoparticle number density (particles per mL)
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(1)

Where organic added is a known volume that can be converted into cubic nanometers

(2)

Where r is the radius (nm) determined from light scattering
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(3)

The final number of particles is determined by dividing the total volume of organic by the
volume of the average nanoparticle size (see Table S2, Supporting Information). This
number results in particles per 10 mL (10 mL is the total volume of the emulsified solution),
multiplication of volume added by this number results in the number of particles delivered.
Gas Chromatography–Mass Spectrometry (GC–MS) Release Study of Essentials Oil
Nanoparticles
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Freshly prepared CNPs and TCNPs were transferred in 100 mL volumetric flasks and diluted
1:10 with deionized water. For each diluted suspension, 10 mL aliquots were removed at 0,
4, 8, 12, and 24 h, and NPs were precipitated for 4 h at 40 000 rpm (4 °C) in a Beckman
Coulter Optima XE ultracentrifuge. 200 μL of the supernatant was removed and extracted by
vortexing for 30 s with 800 μL of ethyl acetate. The liquid phases were separated by
centrifugation for 15 min at 13 000 rpm, and the organic layer was transferred to a capped
1.5 mL GC-MS vial. To determine the amounts of EOs in the pre-emulsified organic
monomer mixture, 450 μL of organic stock solution (carvacrol and combo) was diluted
1:100 in ethyl acetate. All samples were placed into capped GC-MS vials and run using the
following protocol.
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GC-MS analysis was performed on an Agilent 6890 GC/MSD equipped with an auto
sampler and a Restek RTx-1 30 meter column. All samples and standards were analyzed
from 1 μL injection volumes. Analysis parameters include an inlet temperature of 200 °C in
splitless mode and a helium flow rate of 30 mL min−1 in gas saver mode. Thermal ramping
conditions used include an initial hold at 45 °C for 4 min followed by an increase in
temperature at 25 °C min−1 up to 140 °C with a 3 min hold at 140 °C. The temperature ramp
continued at 2.5 °C min−1 up to 150 °C with a 3 min hold followed by a final increase at
50 °C min−1 to 220 °C with a 7 min hold (Figure S8, Supporting Information). The method
provided unique separation of thymol and carvacrol isomers eluting at 19.41 and 19.58 min,
respectively (Figure S9, Supporting Information). Calibration curves for both isomers were
prepared in ethyl acetate at 0, 200, 400, 600, 800, and 1000 ng μL−1 (Figure S10, Supporting
Information). A representative chromatogram of extracted nanoparticles depicting the
elution of thymol, carvacol, and hexadecane can be seen in Figure S11 (Supporting
Information).
Evaluation of Antibacterial Activity of Nanoparticles
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The antimicrobial activity of NPs was tested against several species of bacteria using a well
diffusion method. The indicator microorganisms included Escherichia coli ATCC 25922
(serotype O6, biotype 1), E. coli ATCC 43895 (serotype O157:H7), Staphylococcus aureus
RN6390,[49] Bacillus subtilis subsp. spizizenii ATCC 6633, and Burkholderia cenocepacia
K56-2 (clinical isolate from Canada).[50] The testing was done on Mueller Hinton II agar
(MHA) plates that had been overlaid with soft agar seeded with individual bacterial strains.
The soft agar contained (per liter): 10 g of Bacto Tryptone, 6 g of Difco agar, and 8 g of
sodium chloride. To create an overlay, the indicator organisms were grown overnight at
27 °C (B. subtilis) or 37 °C (E. coli, S. aureus, and B. cenocepacia) in MHB. The overnight
cultures were diluted 1:5 with fresh MHB, and mixed with molten soft agar to achieve the
density of ≈108 CFU mL−1. From this mixture, 4 mL aliquots were overlaid onto MHA base
plates and allowed to completely solidify.
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After solidifying of soft agar, 8 mm wells were made and their bottoms were sealed with 20
μL of MHA. Then, 70 μL of each sample was added to the wells and allowed to freely
diffuse into growth medium. Wells containing pure carvacrol or a mixture of carvacrol (1 g)
and thymol (0.6 g) were used as a positive control. Negative controls contained 70 × 10−3 M
Hitenol BC 20, or empty NPs suspended in butyl acetate. The plates were incubated at each
bacterium’s optimum growth temperature as listed above. The zones of inhibition (ZOI)
were measured after 24, 48, and 72 h. Three replicates were carried out for each nanoparticle
treatment and bacterial strain. Experiment was repeated three times to ensure data
reproducibility.
Determination of Minimum Inhibitory Concentrations (MICs)
MICs of nanoparticles were determined using a modified broth microdilution method.[44]
Briefly, overnight bacterial cultures were adjusted to ≈105 CFU mL−1, and nanoparticles
were serially diluted with sterile water to achieve a range of concentrations between 1011 to
107 particles μL−1. In a 96-well microplate, 150 μL aliquots of adjusted bacterial cultures
were mixed with 50 μL aliquots of different NPs. Bacteria suspended in MHB without
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addition of nanoparticles served as a positive control, while MHB without bacterial
inoculum and nanoparticles served as a negative control. The inoculated microplates were
incubated at each bacterium’s optimum growth temperature, and the susceptibility of
microorganisms to different NPs was assessed by measuring optical density at 600 nm. The
results were expressed as % viability obtained through Equation (4)

(4)

Where OD is the optical density at 600 nm, t0 is the initial time 0 h, and t20 is the time after
20 h of incubation.
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For further verification of inhibition of bacterial growth, 10 μL of bacterial cultures treated
for 20 h with different nanoparticles were plated on MHA and incubated at each bacterium’s
optimum growth temperature for additional 20 h. The MIC refers to the concentration of
NPs that completely inhibited bacterial growth. Each treatment had four replications and the
experiment was repeated twice.
Viability Staining Assays

Author Manuscript

Bacterial viability was determined by using a LIVE/DEAD BacLight Bacterial Viability Kit
staining kit (Life Technologies). Overnight bacterial cultures were centrifuged at 8500 rpm
for 3 min, supernatants were removed and the bacterial cells were suspended in 0.9% NaCl
at OD600 of 0.1 (≈108 CFU mL−1). Freshly prepared nanoparticles were diluted 1:10 with
sterile water. The adjusted bacterial cultures were mixed with the diluted nanoparticles at a
ratio of 3:1, and incubated at 20 °C in the dark. At 0, 2, 4, 6, 8, 12, and 24 h, 100 μL aliquots
of the bacteria-NP mixtures were transferred into a black flat bottom microplate, and mixed
with 100 μL of the LIVE/DEAD BacLight staining reagent. The samples were incubated in
the dark for 15 min, and fluorescence was measured using a 485/20 nm excitation filter (for
both SYTO9 and PI) and a 528/20 nm (SYTO9 emission wavelength) and a 620/40 nm (PI
emission wavelength) emission filter. For confocal imaging, 5 μL of the stained sample was
cast on a microscope slide. Each sample was assayed in triplicate, and the experiment was
repeated twice. The results of viability staining were confirmed by plating 10 μL of each
bacterial suspension on MHA, and incubating the plates at an appropriate growth
temperature for 20 h.
Terminal Dilution Assays
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To compare the rate of bacterial killing by different NPs, the test organisms were exposed to
NPs and the decline in numbers of viable bacteria was followed by a modified terminal
dilution method.[51] The bacterial cultures were prepared and adjusted to ≈108 CFU mL−1 as
described above. The adjusted bacterial cultures (9 mL) were mixed with nanoparticles (1
mL), and the bacterial populations were determined immediately after the addition of NPs (0
h), and at 2, 4, 8, 12, and 24 h of exposure. At each time point, 100 μL aliquots of the
bacteria-NP suspensions were transferred into 96 well microplates prefilled with 200 μL of
MHB and serially diluted. The inoculated microplates were incubated for 48 h at an
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appropriate growth temperature, after which the turbidity in each well was measured with a
BioTek Synergy 2 microplate reader. An optical density at 600 nm of ≥0.05 was considered
positive for bacterial growth. Populations of viable bacteria were calculated from the final
dilution (terminal dilution, or TD), in which bacterial growth was observed using Equation
(5)

(5)

Where TD is the terminal dilution factor obtained from microplate readings.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

a) The thiol-ene reaction involves alternating chain transfer and propagation b) with various
multifunctional monomers used to generate polythioether nanoparticles via thiol-alkene
photopolymerization in miniemulsion. c) Representative TEM of thymol/carvacrol-loaded
nanoparticles.
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Figure 2.
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a) Amounts of essential oils extracted from the supernatant after pelleting NPs by
ultracentrifugation. b) Calculated release profiles for both CNPs and TCNPs over 24 h.
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Figure 3.

Well diffusion assay identifies treatments with antimicrobial activity. Bacteria were
incubated with a) Hitenol BC-20 (70 × 10−3 M), b) ControlNPs, c) CNPs, and d) TCNPs at
1013 NPs mL−1. Zones of inhibition (ZOI, mm) are reported below each image.
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Figure 4.

Percent viability of various bacteria upon treatment with TCNPs. The 0 μg mL−1 EO {1011}
was treated with ControlNPs. Inset images show the corresponding spot tests for the presence
of live bacteria.
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Figure 5.

Effect of TCNPs on the viability of a) B. subtilis ATCC 6633 and b) E. coli ATCC 25922, as
monitored by confocal laser scanning microscopy. Representative images of control cultures
(top row), and cultures treated with 1011 TCNPs (middle and bottom row) at the indicated
time points. The green signal (SYTO 9) indicates viable live cells, whereas red signal
(propidium iodide) indicates damaged or dead cells. Scale bars = 10 μm.
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Figure 6.
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Evaluation of antimicrobial activity for 1011 TCNPs mL–1 on the viability of (●) E. coli
ATCC 25922, (■) S. aureus RN6390, (▲) B. subtilis ATCC 6633, (▼) E. coli ATCC 43895
(serotype O157:H7), and (◆) B. cenocepacia K56-2 via a) a kinetic terminal dilution and b)
percentage of bacteria killed and over 48 h. *Dashed line represents the limit of quantitation.
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Figure 7.

a) TEM of E. coli ATCC 25922 and b) B. subtilis ATCC 6633 control cultures and cultures
that were challenged with 1011 TCNPs for various times. c) High resolution SEM of the
control culture of B. subtilis ATCC 6633 and the culture treated for 24 h with 1011 TCNPs.
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